Blueprint Genetics raises €14M to furter develop AI-enabled clinical genetic testing solutions.
Blueprint Genetics, a Helsinki, Finland-based provider of clinical genetic testing for the diagnosis of inherited diseases announced raising €14M ($16M) in a new investment round.
The money comes from an international syndicate of investors, led by new ones, German Creathor Venture and Swiss MTIP, and including the existing shareholders Inventure, Pontos Group and Stanford University.
Blueprint Genetics, founded in 2012 as a spinoff from Stanford University, is a genetic knowledge company that provides comprehensive genetic testing services.
Blueprint covers the entire workflow from patient sample to automated clinical interpretation of the results provided in a ready-to-use report, using CLINT, its artificial intelligence platform, together with its proprietary targeted sequencing technology, OS-Seq, developed at Stanford. The company, led by CEO Tommi Lehtonen, works with more than 450 hospital customers in over 40 countries.
Prior to this investment, Blueprint Genetics raised €9M in outside capital.